We are live on ! Find out more
178.88 USD
-1.17
0.65%
At close Updated Aug 27, 4:00 PM EDT
Pre-market
After hours
178.88
0.00
0%
1 day
-0.65%
5 days
2.07%
1 month
-24.3%
3 months
-8.23%
6 months
14.45%
Year to date
56.21%
1 year
30.04%
5 years
36.75%
10 years
177.72%
 

About: DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

Employees: 78,000

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 70.5%
Neutral 24.6%
Negative 4.9%
Neutral
The Motley Fool
17 hours ago
Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)
In fact, it's a healthcare company. It is a strong player in its chosen niche.
Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)
Positive
Zacks Investment Research
1 day ago
DVA & Humana Expand Value-Based Care for Kidney Disease Patients
DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.
DVA & Humana Expand Value-Based Care for Kidney Disease Patients
Neutral
PRNewsWire
2 days ago
Alebund Pharmaceuticals Announces 2026 Interim Results
SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.
Alebund Pharmaceuticals Announces 2026 Interim Results
Neutral
PRNewsWire
3 days ago
DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease
More than 10,000 members will get added support aimed at delaying or preventing dialysis and reducing hospitalizations DENVER, Aug. 25, 2026 /PRNewswire/ -- DaVita today announced a new value-based care agreement to deliver comprehensive, coordinated care to Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5. Launched July 1, this partnership builds on the organizations' long-standing collaboration in end stage kidney disease and expands earlier into the disease journey, when intervention can have the greatest impact.
DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease
Positive
Zacks Investment Research
21 days ago
Is DaVita (DVA) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is DaVita (DVA) a Great Value Stock Right Now?
Negative
Zacks Investment Research
22 days ago
DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down
DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.
DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down
Neutral
Zacks Investment Research
22 days ago
DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth
DaVita's Q2 earnings call highlights mortality-led volume gains and broader middle molecule access, while management held 2026 guidance amid reimbursement pressure.
DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth
Positive
MarketBeat
23 days ago
DaVita Q2 Earnings Call Highlights
DaVita NYSE: DVA reported second-quarter results that management said were broadly in line with expectations, supported by accelerating treatment-volume growth and lower mortality among patients. The kidney-care company reaffirmed its full-year 2026 guidance, while outlining plans to expand access to newer dialysis technology designed to improve clearance of so-called middle molecules.
DaVita Q2 Earnings Call Highlights
Neutral
Seeking Alpha
23 days ago
DaVita Inc. (DVA) Q2 2026 Earnings Call Transcript
DaVita Inc. (DVA) Q2 2026 Earnings Call Transcript
DaVita Inc. (DVA) Q2 2026 Earnings Call Transcript
Negative
Reuters
23 days ago
DaVita flags lower revenue per treatment, reaffirms annual forecast
DaVita said on Tuesday revenue per treatment was lower in the second quarter, blaming declining ​enrollments for dialysis treatments as patients dropped ‌out of Obamacare plans following the end of pandemic-era subsidies.
DaVita flags lower revenue per treatment, reaffirms annual forecast
Price charts implemented using Lightweight Charts™